A5064884287- Botulinum Toxin and Related Neurological Disorders
- Intramuscular injections and effects
- Advancements in Transdermal Drug Delivery
- SARS-CoV-2 and COVID-19 Research
- Viral gastroenteritis research and epidemiology
- Bacillus and Francisella bacterial research
- Diabetes Management and Research
- Advanced Drug Delivery Systems
BD Technologie (United States)
2005-2023
Determining feasibility and tolerability of large volume viscous subcutaneous injection may enable optimized, intuitive delivery system design. A translational early clinical study examined viability, tolerability, acceptability, tissue effects depot location for ~1, 8, 20 cP injections at volumes up to 10 ml in the abdomen 5 thigh 32 healthy adult subjects. commercial syringe pump delivered 192 randomized, constant rate (20 µl/s) (6/subject) with in-line pressure captured versus time....
Subcutaneous (SC) delivery is a preferred route of administration for biotherapeutics but has predominantly been limited to volumes below 3 mL. With higher volume drug formulations emerging, understanding large SC (LVSC) depot localization, dispersion, and impact on the environment become more critical. The aim this exploratory clinical imaging study was assess feasibility magnetic resonance (MRI) identify characterize LVSC injections their effect tissue as function site volume. Healthy...
An investigational wearable injector (WI), the BD Libertas Wearable Injector (BD is a trademark of Becton, Dickinson and Company), was evaluated in an early feasibility clinical study for functional performance, tissue effects, subject tolerability, acceptability 5 mL, non-Newtonian ~ 8 cP subcutaneous placebo injections 52 healthy adult subjects 2 age groups (18-64 years ≥ 65 years). Randomized WI (n = 208, 4/subject) were delivered to right left abdomen thigh each subject, 50% (1 1...